TD Asset Management Inc Sells 25,321 Shares of IDEXX Laboratories, Inc. $IDXX

TD Asset Management Inc reduced its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.7% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 304,190 shares of the company’s stock after selling 25,321 shares during the period. TD Asset Management Inc’s holdings in IDEXX Laboratories were worth $194,344,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the third quarter valued at about $31,000. Armstrong Advisory Group Inc. increased its position in shares of IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the last quarter. Salomon & Ludwin LLC bought a new position in shares of IDEXX Laboratories in the 3rd quarter worth approximately $35,000. Greykasell Wealth Strategies Inc. purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $35,000. Finally, WealthCollab LLC bought a new stake in IDEXX Laboratories during the second quarter valued at approximately $30,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

IDXX has been the subject of a number of research reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $830.00 target price on shares of IDEXX Laboratories in a report on Tuesday, November 4th. UBS Group cut their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating for the company in a research report on Tuesday, February 3rd. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $675.00 to $775.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Leerink Partners set a $785.00 target price on IDEXX Laboratories in a research report on Monday, November 3rd. Finally, Piper Sandler cut their price target on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. Seven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $783.33.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director Sophie V. Vandebroek sold 1,464 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total transaction of $920,299.68. Following the completion of the sale, the director directly owned 648 shares of the company’s stock, valued at $407,345.76. This trade represents a 69.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP George Fennell sold 11,345 shares of the business’s stock in a transaction on Tuesday, February 10th. The stock was sold at an average price of $646.72, for a total transaction of $7,337,038.40. Following the completion of the transaction, the executive vice president directly owned 9,823 shares in the company, valued at $6,352,730.56. This trade represents a 53.60% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 18,180 shares of company stock valued at $11,626,996. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Stock Up 1.3%

IDXX opened at $657.38 on Thursday. The stock has a market cap of $52.34 billion, a price-to-earnings ratio of 50.30, a price-to-earnings-growth ratio of 3.94 and a beta of 1.67. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. The firm’s fifty day moving average is $674.55 and its 200 day moving average is $668.99. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Monday, February 2nd. The company reported $2.92 EPS for the quarter, missing analysts’ consensus estimates of $2.93 by ($0.01). IDEXX Laboratories had a net margin of 24.62% and a return on equity of 69.78%. The business had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the prior year, the business earned $2.53 earnings per share. IDEXX Laboratories’s revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.